CX3CL1/CX3CR1 Axis, as the Therapeutic Potential in Renal Diseases: Friend or Foe?

被引:38
|
作者
Zhuang, Quan [1 ]
Cheng, Ke [1 ]
Ming, Yingzi [1 ]
机构
[1] Cent South Univ, Xiangya Hosp 3, Transplantat Ctr, 138 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China
关键词
Fractalkine; CX3CL1; Chemokine receptor; CX3CR1; Renal disease; Kidney transplantation; FRACTALKINE RECEPTOR CX3CR1; DENDRITIC CELLS; IGA NEPHROPATHY; T-CELLS; LEUKOCYTE RECRUITMENT; ENDOTHELIAL-CELLS; TNF-ALPHA; EXPRESSION; CHEMOKINE; INFLAMMATION;
D O I
10.2174/1566523218666180214092536
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
The fractalkine receptor chemokine (C-X3-C motif) receptor 1 (CX3CR1) and its highly selective ligand CX3CL1 mediate chemotaxis and adhesion of immune cells, which are involved in the pathogenesis and progression of numerous inflammatory disorders and malignancies. The CX3CL1/CX3CR1 axis has recently drawn attention as a potential therapeutic target because it is involved in the ontogeny, homeostatic migration, or colonization of renal phagocytes. We performed a Medline/PubMed search to detect recently published studies that explored the relationship between the CX3CL1/CX3CR1 axis and renal diseases and disorders, including diabetic nephropathy, renal allograft rejection, infectious renal diseases, IgA nephropathy, fibrotic kidney disease, lupus nephritis and glomerulonephritis, acute kidney injury and renal carcinoma. Most studies demonstrated its role in promoting renal pathopoiesis; however, several recent studies showed that the CX3CL1/CX3CR1 axis could also reduce renal pathopoiesis. Thus, the CX3CL1/CX3CR1 axis is now considered to be a double-edged sword that could provide novel perspectives into the pathogenesis and treatment of renal diseases and disorders.
引用
收藏
页码:442 / 452
页数:11
相关论文
共 50 条
  • [1] The Impact of the CX3CL1/CX3CR1 Axis in Neurological Disorders
    Pawelec, Paulina
    Ziemka-Nalecz, Malgorzata
    Sypecka, Joanna
    Zalewska, Teresa
    [J]. CELLS, 2020, 9 (10) : 1 - 17
  • [2] CX3CR1/CX3CL1 axis in breast cancer pathology and its therapeutic use
    Singh, Rajesh
    Singh, Santosh Kumar
    Mishra, Manoj K.
    Lillard, James W.
    [J]. JOURNAL OF IMMUNOLOGY, 2020, 204 (01):
  • [3] Role of CX3CL1/CX3CR1 Signaling Axis Activity in Osteoporosis
    Wojdasiewicz, Piotr
    Turczyn, Pawel
    Dobies-Krzesniak, Barbara
    Frasunska, Justyna
    Tarnacka, Beata
    [J]. MEDIATORS OF INFLAMMATION, 2019, 2019
  • [4] CX3CL1/CX3CR1 signaling targets for the treatment of neurodegenerative diseases
    Subbarayan, Meena S.
    Joly-Amado, Aurelie
    Bickford, Paula C.
    Nash, Kevin R.
    [J]. PHARMACOLOGY & THERAPEUTICS, 2022, 231
  • [5] The effect of CX3CL1/CX3CR1 signal axis on microglia in central nervous system diseases
    Zhao, Jianhua
    Li, Qiong
    Ouyang, Xiantao
    Wang, Fan
    Li, Qing
    Xu, Zhixiu
    Ji, Danxia
    Wu, Qingwu
    Zhang, Jian
    Lu, Chengbiao
    Ji, Sibei
    Li, Shaomin
    [J]. JOURNAL OF NEURORESTORATOLOGY, 2023, 11 (01):
  • [6] Regulation of microglia neurotoxicity by CX3CR1 and CX3CL1
    Cardona, AE
    Huang, DR
    Sasse, ME
    Kidd, G
    Lira, S
    Cook, D
    Jung, S
    Littman, D
    Ransohoff, R
    [J]. FASEB JOURNAL, 2005, 19 (04): : A940 - A940
  • [7] Therapeutic intervention of inflammatory/ immune diseases by inhibition of the fractalkine (CX3CL1)-CX3CR1 pathway
    Imai T.
    Yasuda N.
    [J]. Inflammation and Regeneration, 36 (1)
  • [8] Role of fractalkine/CX3CL1 and its receptor CX3CR1 in allergic diseases
    Julia, Valerie
    Staumont-Salle, Delphine
    Dombrowicz, David
    [J]. M S-MEDECINE SCIENCES, 2016, 32 (03): : 260 - 266
  • [9] Chemokines and atherosclerosis: focus on the CX3CL1/CX3CR1 pathway
    Stavros Apostolakis
    Demetrios Spandidos
    [J]. Acta Pharmacologica Sinica, 2013, 34 : 1251 - 1256